Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1611—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
  • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
  • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5021—Organic macromolecular compounds
  • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
  • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
  • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
  • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/32—Alcohol-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the subject of the present invention is a novel composition based on gamma-hydroxybutyric acid or a pharmaceutically acceptable salt thereof, as well as the process for preparing the aforementioned composition.
• ⁇ -Hydroxybutyric acid (or GHB) is considered to be an endogenous neuromodulator or neurotransmitter present in the human brain. It is a metabolite of ⁇ -aminobutyric acid (GABA).
• GABA ⁇ -aminobutyric acid
• the drug Xyrem ® comprising as active ingredient a sodium salt of GHB, namely sodium hydroxybutyrate (or sodium oxybate, Nahoo), is used for the treatment of narcolepsy in adult patients with cataplexy .
• GHB is also used as anesthetic. It also has a mimetic effect of alcohol on the central nervous system.
• GHB has a short half-life, peak plasma concentration, rapid elimination and variable (low) bioavailability depending on the diet.
• GHB has a short half-life, peak plasma concentration, rapid elimination and variable (low) bioavailability depending on the diet.
• sodium hydroxybutyrate is absorbed very rapidly by the gastroenteric tract with a peak peak of about 30-45 minutes after administration and has a half-life of about 20 minutes. -25 minutes.
• its elimination is very fast (in about 4 to 5 hours).
• This pharmacokinetic profile therefore involves the administration of a large daily dose of 4 to 9 g, repeated doses every 3 to 4 hours, and in particular in the middle of the night for narcoleptic patients, which results in an effective limited due to large variations in plasma concentration and a risk of intolerance due to these variations.
• the existing galenic forms do not make it possible to improve this profile.
• oral solutions are constraining in terms of compliance and can cause problems of stability and conservation.
• GHB is unstable in acidic medium, the possible gastric degradation of GHB and thus a decrease in bioavailability can not be ruled out.
• the present invention aims to provide a new galenic form based on gamma-hydroxybutyric acid or a salt thereof (especially sodium) to overcome the aforementioned drawbacks.
• the present invention aims to provide a new dosage form based on gamma-hydroxybutyric acid or a salt thereof to reduce the daily dose and the number of daily doses, increasing the apparent half-life and the bioavailability of the active ingredient.
• the present invention aims to provide a new galenic form based on gamma-hydroxybutyric acid or a salt thereof to reduce or eliminate side effects by reducing the plasma concentrations used.
• the present invention aims to provide a new galenic form based on gamma-hydroxybutyric acid or a salt thereof to improve the comfort of the patient and the monitoring of treatment by reducing the number of daily doses, especially avoiding nocturnal catch.
• the present invention aims to provide a new galenic form based on gamma-hydroxybutyric acid or a salt thereof to improve the safety of the product with a stable dosage form and avoiding or reducing deflections of use.
• the present invention relates to a gamma-hydroxybutyric acid granule or a pharmaceutically acceptable salt thereof, characterized in that it comprises a solid core on which is supported gamma-hydroxybutyric acid or a salt thereof.
• the active ingredient used is in salt form, and more particularly in the form of sodium salt (sodium salt of 4-hydroxybutyric acid or sodium oxybate).
• granule refers to a preparation consisting of dry solid grains, each forming an aggregate of powder particles of sufficient strength to allow various manipulations. Generally, the granules are in the form of small grains of irregular and angular shape. However, the granules according to the present invention have the particularity of having a fairly regular shape, homogeneous and almost spherical.
• the granules are aggregates of crystallized or amorphous powders of various powders.
• the granules of the present invention are intended for oral administration, and more particularly to be swallowed as such.
• the granules of the present invention have a characteristic structure of the heart-bark type, the heart not being of the same nature as the active principles forming the bark.
• the core of the granules may however comprise particles of ⁇ -hydroxybutyric acid or a salt thereof.
• these granules have a multilayer structure. Indeed, the active ingredient ( ⁇ -hydroxybutyric acid or one of its salts) is deposited on the heart and thus forms a layer (or bark) deposited around the heart (or support).
• the active ingredient ⁇ -hydroxybutyric acid or one of its salts
• the heart of the granules can also be considered as being a support on which the particles of the active principle will be fixed.
• the heart consists of solid particles and the active ingredient supported by said heart is also in solid form.
• the present invention is therefore based on the development of a new multi-particle oral form.
• the originality of the form presented here consists of a granule for the oral route, allowing the administration of ⁇ -hydroxybutyric acid or a salt thereof at doses large enough to require only one or two administrations per day, the granule of the invention being highly concentrated in active principle.
• the granules of the present invention have the advantage of allowing a reduction in the number of daily doses for the patient.
• the core of the granules of the invention consists of particles of a compound selected from the group consisting of polyols such as mannitol, sorbitol, maltitol or xylitol, lactose, dicalcium phosphate. , carbonates such as calcium carbonate, potassium carbonate, magnesium or sodium carbonate, gluconates, silicates, especially magnesium aminosilicate (Neusilin ® ), sugar crystals, sucrose, silica derivatives and derivatives starch.
• polyols such as mannitol, sorbitol, maltitol or xylitol
• lactose dicalcium phosphate
• carbonates such as calcium carbonate, potassium carbonate, magnesium or sodium carbonate
• gluconates silicates, especially magnesium aminosilicate (Neusilin ® ), sugar crystals, sucrose, silica derivatives and derivatives starch.
• the core of the granules of the invention consists of mannitol.
• the heart of the granules does not consist of neutral nuclei.
• the present invention therefore relates to granules comprising ⁇ -hydroxybutyric acid (or a salt thereof) deposited on a core consisting of mannitol particles.
• the core of the granules according to the present invention does not comprise any cellulosic compound.
• the aforementioned granules also comprise a binder.
• the role of the binder is to bind the particles together, that is to say, to perfect the cohesion of the granule.
• the binders make it possible to ensure good cohesion of the active ingredient and the core in the granules.
• the binders are, like the active ingredient, deposited around the heart of the granules.
• binders mention may be made of most of the hydrophilic excipients which give viscous solutions: gum arabic and tragacanth, methylcellulose and carboxymethylcellulose, gelatin, starches, maltodextrins, PEG 4000 and 6000 in alcoholic solution, polyvidone in aqueous or alcoholic solution, and also solutions of sucrose, glucose or sorbitol.
• the binders of the granules of the invention are preferably selected from the group consisting of starch, sucrose, gum arabic, polyvinylpyrrolidone (PVP or polyvidone), hydroxypropyl methylcellulose (HPMC), shellac , hydroxypropylcellulose (HPC), cellulose, polyols or alginates, polyglycolized glycerides (Gelucire ®) or macrogolglycerides, in particular stearoyl macrogolglycerides, also acrylic derivatives and mixtures thereof.
• polystylitol there may be mentioned in particular mannitol, sorbitol, maltitol or xylitol.
• the binders used in the granules of the present invention are not cellulosic compounds. They are therefore preferably selected from the group consisting of polyvinylpyrrolidone, shellac, polyols or alginates, polyglycolysed glycerides (Gelucire) or macrogolglycerides, especially stearoyl macrogolglycerides, and mixtures thereof. It is also possible to use a binder chosen from the groups mentioned above for particular properties; for example, it may be useful to use pH-dependent excipients such as EUDRAGIT ® L100 or shellac as binder.
• the granules of the invention are coated.
• the coated granules consist of grains coated with one or more layers of mixtures of various excipients.
• the preferred coated granules according to the present invention comprise the active ingredient deposited on a core consisting of mannitol particles, as well as an additional layer consisting of the coating agent.
• the granules of the invention have a multilayer structure and consist of a core, preferably based on mannitol, on which are deposited the active ingredient (GHB) and the binder, themselves coated. one or more layers of coating agent (s).
• the granules of the invention are preferably coated with a coating agent selected from the group consisting of shellac, polyvinylpyrrolidone, polyethylene glycol (PEG), cellulosic derivatives such as HPMC or HPC, sucrose, alginate, glycerides of fatty acids and methacrylic polymers.
• the granules of the invention are coated with shellac.
• the granules of the invention may also be coated with a coating film in which one or more excipients such as lubricants, dyes, sweeteners, plasticizers or antiblocking agents are added.
• excipients such as lubricants, dyes, sweeteners, plasticizers or antiblocking agents are added.
• the granules of the invention may also comprise an enteric coating for gastric protection. Such granules are therefore gastroresistant.
• Such a coating is obtained with coating agents including HPMCP (hydroxypropylmethylcellulosephthalate - hypromellose phthalate) or methacrylic polymers, including Eudragit ® L, or shellac.
• HPMCP hydroxypropylmethylcellulosephthalate - hypromellose phthalate
• methacrylic polymers including Eudragit ® L, or shellac.
• the presence of this enteric coating can influence the bioavailability of the active ingredient (GHB or Na-GHB), in particular by avoiding its degradation in acidic medium.
• the granules of the invention may also comprise a coating for sustained release.
• Such granules allow a modified or delayed release of the active ingredients (modified release granules).
• Such a coating is obtained with coating agents in particular consisting of copolymers of methacrylates and acrylates Eudragit ® S100, shellac, cellulose derivatives, especially ethylcellulose, and acrylic derivatives.
• the presence of this coating for modified release notably influences the apparent half-life of the active ingredient (in particular GHB or Na-GHB).
• the granules according to the present invention may also comprise a lubricant and / or an aroma and / or a sweetener and / or a colorant.
• talc magnesium stearate
• silica derivatives especially Aerosil ®
• waxes waxes
• flavors used in the context of the present invention mention may be made of the flavors conventionally used in food additives.
• sweeteners used in the context of the present invention are in particular those listed in Directive 94/35 / EC of 30 June 1994 on sweeteners for use in foodstuffs (as amended by Directive 2006/25 / EC). July 5, 2006). Thus, mention may be made of aspartame E
• the dyes used in the context of the present invention are in particular those listed in Directive 95/45 / EC of 26 July 1995 on colorants that may be used in foodstuffs (as amended by Directive 2006/33 / EC of 20 March 2006). Thus, we can notably mention the dyes
• insoluble excipients can also be used to prevent total solubilization of the granule for diverted and malicious use.
• the granules of the invention may also contain one or more plasticizers such as those conventionally used by those skilled in the art.
• a granule according to the present invention comprises at least 35% by weight of gamma-hydroxybutyric acid or a salt thereof, and preferably at least 45% by weight of gamma-hydroxybutyric acid or of one of its salts.
• the granules of the present invention comprise from 35% to 65% by weight of gamma-hydroxybutyric acid or a salt thereof.
• the core of a granule of the invention represents from 20% to 80%, and preferably from 30% to 55%, or even 35% to 55% by weight relative to the total weight of said granule .
• the granules of the invention preferably comprise from 0 to 10%, and preferably from 4 to 8%, by weight of binder.
• the granules of the invention preferably comprise from 10% to 45%, and preferably from 20% to 30%, by weight of coating agent.
• the granules of the invention preferably comprise less than 3% by weight of flavor.
• the granules of the invention preferably comprise less than 2% by weight of dye.
• the granules of the invention preferably comprise less than 1.5% by weight of sweetener.
• the granules of the invention preferably comprise less than 4% by weight of lubricant.
• the granules of the invention may also comprise a plasticizer, especially triethyl citrate, in a proportion of less than 3% by weight.
• the present invention also relates to a pharmaceutical composition comprising granules as defined above.
• the present invention also relates to the granules of the invention as defined above, for their use for the treatment of catalepsy in narcoleptic patients.
• the present invention also relates to the granules of the invention as defined above, for their use for the weaning of alcoholism.
• the granules according to the invention can be packaged in individual containers, for example in sachets, sticks, paper bags or flasks, and preferably in plastic ampoules.
• the granules of the present invention have the advantage of reducing the number of daily intakes.
• the amount of ⁇ -hydroxybutyric acid (or a salt thereof) per unit dosage is preferably greater than or equal to 500 mg, advantageously greater than or equal to 1 g, and preferably greater than or equal to 1, 5 g.
• the granules according to the present invention can be ingested directly or be dispersed in a solution, or mixed in a food carrier such as yogurt or compote.
• the present invention also relates to a process for the preparation of a granule as defined above, characterized in that it comprises a step of powder coating with gamma-hydroxybutyric acid or a salt thereof on a solid particulate support.
• the method of the invention therefore consists in mixing the active ingredient ⁇ -hydroxybutyric acid (or a salt thereof) in powder form in the presence of solid particles as a carrier.
• the solid particles of the support used form a core on which the particles of the active ingredient are deposited.
• the structure of the granules of the invention is therefore related to the implementation of this particular process which makes it possible to obtain pellets of core-shell structure.
• the granules of the present invention are characterized in that they have a lowered specific surface area. Moreover, in appearance, they are relatively smooth and have a rather regular shape.
• the above-mentioned powdering step of the process for the preparation of the granules of the invention may also comprise a step of spraying an alcoholic or aqueous-alcoholic or aqueous solution of a binder.
• This spraying step and the dusting step are preferably carried out simultaneously or alternately.
• the above-mentioned dusting step is carried out concomitantly with a step of spraying a binder in the form of a solution.
• An advantageous implementation of the process of the invention thus consists in applying the active ingredient in powder form to the particulate support mentioned above (or core of the granules) by alternating binder spraying sequences in the form of a solution.
• the method of the invention may also comprise, after the dusting step, one or more coating steps of the granule, in particular by coating the coating agent (s) in the form of films on the granule.
• the low specific surface area of the granules of the invention thus makes it possible, in case of coating, to reduce the amount of coating agent used and thus to dilute the active ingredient in said coated granules less.
• a preferred embodiment of the process of the invention consists of a process comprising, after the coating step, a step of mixing with a lubricant and / or a flavor and / or a sweetener and / or a colorant, these they can themselves be prepared in the form of granules in order to be finally mixed with the active granules.
• lubricants may also be added before the aforementioned powdering step.
• the aforementioned method may also comprise, before the dusting step, a step of grinding the active ingredient (GHB) in the presence of a diluent.
• the process comprises a grinding step, it may be followed by a step of adding the lubricants, flavors, sweeteners and colorants.
• the process for preparing the granules of the invention comprises the following steps:
• the ingredients are weighed one by one, then the active ingredient is introduced into a cubic mixer.
• the amount of diluent is in turn weighed (mannitol 160) and introduced into the mixer.
• the mixer is then started.
• the mixture obtained (A) is satisfactory after 10 minutes.
• the mixture is then introduced into a Forplex FLO mill and the entire mixture is milled so as to reduce the particle size of the assembly (active ingredient + diluent).
• This makes it possible to increase the difference in size of the particles of mannitol (support) (approximately 300 ⁇ ) and of the ground mixture (less than 100 ⁇ and preferably 25 ⁇ ).
• the next step of the process is a dusting step using a conventional turbine as a material.
• the support mannitol is introduced into a tank, it is then rotated (about 20 revolutions per minute) and the mixture A is deposited by sequential dusting on the support mannitol, alternatively with spraying phases of the binding solution (PVP / HPMC / OH / H 2 O).
• This step is done sequentially to allow evaporation and drying of the granules.
• a drying phase is carried out so as to circulate on the mass of granules hot air at about 40 ° C. for about 14 hours.
• the product is sieved so as to select the particles obtained.
• the mixture is then returned to the tank.
• the next step is the coating step.
• the solutions (or suspensions) containing the coating agents are placed successively in a low pressure tank with stirring.
• the mass of granules obtained is then placed in the tank of a fluidized air bed and the coating solutions are then sprayed. successively continuously on the granules. Drying / coating steps can also be performed.
• a fluidised air bed apparatus (or related technology) is preferably used for the coating step for their high efficiency in terms of evaporation, which makes it possible to reduce the coating times considerably.
• additives such as sweeteners, lubricants, flavorings and dyes in the form of granules or not can be added to the granules in a mixer.
• the last step is to distribute the granules in individual packaging bags such as plastic ampoules or sachets.

Landscapes

• Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Inorganic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Addiction (AREA)
• Psychiatry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (23)

Applications Claiming Priority (2)

Publications (1)

Family

ID=40674006

Family Applications (1)

Country Status (34)

Cited By (16)

Families Citing this family (14)

Citations (5)

Family Cites Families (27)

• 2008
  • 2008-11-14 FR FR0857763A patent/FR2938431B1/fr not_active Expired - Fee Related
• 2009
  • 2009-11-10 CN CN201510047649.3A patent/CN104688691A/zh active Pending
  • 2009-11-10 CN CN2009801457609A patent/CN102215822A/zh active Pending
  • 2009-11-10 HR HRP20191911TT patent/HRP20191911T1/hr unknown
  • 2009-11-10 PL PL09768176T patent/PL2349217T3/pl unknown
  • 2009-11-10 JP JP2011543797A patent/JP2012508784A/ja active Pending
  • 2009-11-10 UA UAA201105987A patent/UA103057C2/ru unknown
  • 2009-11-10 ES ES09768176T patent/ES2749803T3/es active Active
  • 2009-11-10 DK DK09768176T patent/DK2349217T3/da active
  • 2009-11-10 CA CA2743767A patent/CA2743767C/fr active Active
  • 2009-11-10 LT LT09768176T patent/LT2349217T/lt unknown
  • 2009-11-10 MX MX2011005073A patent/MX2011005073A/es active IP Right Grant
  • 2009-11-10 PE PE2011001031A patent/PE20120028A1/es not_active Application Discontinuation
  • 2009-11-10 EP EP09768176.1A patent/EP2349217B1/fr active Active
  • 2009-11-10 US US13/129,130 patent/US8529954B2/en active Active
  • 2009-11-10 NZ NZ592850A patent/NZ592850A/xx not_active IP Right Cessation
  • 2009-11-10 SM SM20190721T patent/SMT201900721T1/it unknown
  • 2009-11-10 WO PCT/FR2009/052169 patent/WO2010055260A1/fr not_active Ceased
  • 2009-11-10 EA EA201100758A patent/EA023305B1/ru not_active IP Right Cessation
  • 2009-11-10 HU HUE09768176A patent/HUE046321T2/hu unknown
  • 2009-11-10 KR KR1020117013587A patent/KR101563390B1/ko active Active
  • 2009-11-10 AU AU2009315441A patent/AU2009315441B2/en not_active Ceased
  • 2009-11-10 BR BRPI0916021A patent/BRPI0916021B8/pt not_active IP Right Cessation
  • 2009-11-10 PT PT97681761T patent/PT2349217T/pt unknown
  • 2009-11-10 SI SI200932005T patent/SI2349217T1/sl unknown
  • 2009-11-13 TW TW098138675A patent/TWI446906B/zh active
  • 2009-11-16 AR ARP090104424A patent/AR074351A1/es unknown
• 2011
  • 2011-05-11 TN TN2011000231A patent/TN2011000231A1/fr unknown
  • 2011-05-12 IL IL212847A patent/IL212847A/en active IP Right Grant
  • 2011-05-13 MA MA33838A patent/MA32790B1/fr unknown
  • 2011-05-13 CU CU20110109A patent/CU20110109A7/es unknown
  • 2011-05-13 CO CO11059012A patent/CO6382106A2/es not_active Application Discontinuation
  • 2011-05-13 CL CL2011001114A patent/CL2011001114A1/es unknown
  • 2011-05-13 ZA ZA2011/03542A patent/ZA201103542B/en unknown
• 2019
  • 2019-10-30 CY CY20191101121T patent/CY1122209T1/el unknown

Patent Citations (5)

Also Published As

Similar Documents

Legal Events